PDL BioPharma, Inc. (PDLI)

HEALTH CARE: PHARMACEUTICALS
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

932 SOUTHWOOD BLVD INCLINE VILLAGE, NV 89451

PDL BioPharma Inc. is a biopharmaceutical company focused on the discovery and development of novel antibodies in oncology and immunologic diseases. It receives royalties and other revenues through licensing agreements with various biotechnology and pharmaceutical companies based on its antibody humanization technology platform. These licensing agreements have contributed to the development by the Company's licensees of nine marketed products. The Company has several investigational compounds in clinical development for severe or life-threatening diseases, two of which it is developing in collaboration with Biogen Idec MA, Inc. (Biogen Idec). Its products include Daclizumab, Volociximab, HuLuc63, PDL192 and Nuvion. In March 2008, the Company closed the sale of the Cardiovascular Assets, which included Cardene, to EKR Therapeutics, Inc (EKR). However, the Company continues to perform development work for new formulations and presentations of Cardene pursuant to an agreement with EKR.

Data based on most recent fiscal year report
Market Cap365.408 Million Shares Outstanding114.19 Million Avg Volume1.832 Million
1-Yr BETA vs S&P TR0.772 Current Ratio9.86 Quick Ratio9.5
View SEC Filings from PDLI instead.

View recent insider trading info

Funds Holding PDLI (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding PDLI BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

O'FARRELL ELIZABETH G.

  • Director
3,000 2020-01-10 1

STONE CHRISTOPHER LEWIS VP, GEN. COUNSEL & SECRETARY

  • Officer
621,029 2020-01-08 3

MONNET DOMINIQUE PRESIDENT AND CEO

  • Officer
1,907,426 2020-01-08 3

JENE JILL M. VP, BUSINESS DEVELOPMENT

  • Officer
194,805 2020-01-08 3

IMBROGNO EDWARD VP FINANCE, CAO AND ACTING CFO

  • Officer
314,565 2020-01-08 2

MURRAY RICHARD /CA/ CEO AND PRESIDENT

  • Officer
  • Director
87,360 2020-01-07 0

LINDELL JODY S

18,804 2020-01-06 0

KLEIN JOSEPH III

  • Director
12,783 2019-12-23 0

YANAI SHLOMO

  • Director
0 2019-12-14 1

MCCAMISH MARK ANTHONY PRESIDENT AND CEO

  • Officer
  • Director
0 2019-12-13 0

EDICK PAUL R SEE REMARKS

  • Officer
  • Director
186,365 2019-11-25 0

LYONS GARY A

  • Director
225,697 2019-11-08 0

SAXE JON S

0 2019-10-21 0

FRANK FRED

  • Director
0 2019-10-15 0

GRYSKA DAVID W

  • Director
48,013 2019-10-01 1

MCLAUGHLIN JOHN PETER

  • Director
0 2019-09-05 1

SARENA FRANCIS WILLARD CHIEF STRATEGY OFFICER

  • Officer
82,248 2019-09-01 0

PIETZKE STEFFEN VP FIN & CHIEF ACCT OFFICER

  • Officer
0 2019-08-22 0

GUGGENHIME ANDREW CFO

40,927 2019-08-15 0

SANDMAN PAUL W

  • Director
0 2019-06-20 1

SELICK HAROLD E

  • Director
0 2019-06-20 1

SAKS SAMUEL R

  • Director
0 2019-06-20 1

HERNDAY NATASHA

  • Director
0 2019-06-20 2

CROSS HERB CHIEF FINANCIAL OFFICER

  • Officer
0 2019-06-19 0

DAWES KAREN A

  • Director
117,034 2019-06-17 0

GAGE L PATRICK

  • Director
0 2019-06-10 0

GOODWIN BRADFORD S

  • Director
0 2019-05-23 0

HORA MANINDER SVP PHARMA DEV & MFG OPS

  • Officer
94,694 2019-05-16 0

SHAH JAISIM

  • Director
0 2019-04-19 0

GARCIA PETER S VICE PRESIDENT, CFO

  • Officer
0 2019-03-28 2

WILSON KAREN J SVP, FINANCE & PAO

  • Officer
18,385 2019-03-05 0

HART DANNY J JR. VP BUSINESS DEVELOPMENT

  • Officer
387,236 2017-03-04 0

IMMUNE RESPONSE BIOPHARMA, INC.

  • SHAREHOLDER
1 2015-05-17 0

MONTEZ DAVID CONTROLLER AND CAO

  • Officer
26,719 2015-01-28 0

LARSON CHRISTINE R VP AND CHIEF FINANCIAL OFFICER

  • Officer
0 2012-08-13 0

TOMLINSON BRUCE CHIEF FINANCIAL OFFICER

  • Officer
16,509 2012-06-21 0

KRUMEL CAROLINE J VPFINANCE/PRIN.ACCTING OFFICER

  • Officer
9,384 2012-01-18 0

KORN LAURENCE JAY

  • Director
0 2008-05-28 0

IWANICKI DAVID VP, SALES & SALES OPERATIONS

  • Officer
0 2008-01-02 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

IMBROGNO EDWARD - Officer VP FINANCE, CAO AND ACTING CFO

2020-01-08 A 292,208 a 314,565 314,565.00 direct

MONNET DOMINIQUE - Officer PRESIDENT AND CEO

2020-01-08 A 1,233,766 a 1,907,426 1,907,426.00 direct

STONE CHRISTOPHER LEWIS - Officer VP, GEN. COUNSEL & SECRETARY

2020-01-08 A 422,078 a 621,029 621,029.00 direct

JENE JILL M. - Officer VP, BUSINESS DEVELOPMENT

2020-01-08 A 194,805 a 194,805 194,805.00 direct
Click here to report any possible errors with this stock listing.

Elevate your investments